In a striking revelation, internal records indicate that top officials from the Trump administration’s Environmental Protection Agency (EPA) convened with Bayer’s CEO, Bill Anderson, last year to discuss litigation surrounding the company’s glyphosate herbicides. This meeting, held on 17 June, has raised alarm bells regarding the potential influence of corporate interests on regulatory decisions that could impact public health.
High-Stakes Meeting at the EPA
The meeting involved high-ranking EPA officials, including Lee Zeldin, the agency’s administrator, and Nancy Beck, a former senior director at the American Chemistry Council, now serving as principal deputy assistant administrator in the Office of Chemical Safety and Pollution Prevention. According to an internal email from the EPA, the agenda included discussions on “judicial issues” and “supreme court action” related to Bayer’s ongoing legal battles over glyphosate.
Bayer faces numerous lawsuits from individuals alleging that prolonged use of its glyphosate-based products, such as Roundup, has led to cancer diagnoses. The company has consistently maintained that it failed to warn consumers about these risks, despite evidence from multiple studies. Bayer’s strategy hinges on persuading the Supreme Court that if the EPA does not mandate a cancer warning label, the company should not be held liable.
Political Support for Bayer
Since the meeting, the Trump administration has taken several steps that seemingly bolster Bayer’s position. In December, Solicitor General D. John Sauer, appointed by the Trump administration, urged the Supreme Court to hear Bayer’s case, a request that was ultimately granted. The court has scheduled a hearing for 27 April. Furthermore, the White House invoked the Defense Production Act in February to safeguard the production of glyphosate herbicides, effectively granting immunity to Bayer and similar companies.
Critics argue that these actions reflect a concerning trend where corporate interests may unduly influence regulatory agencies. Nathan Donley, director of environmental health science at the Center for Biological Diversity, expressed deep concern over the apparent prioritisation of pesticide company profits over public health.
Industry Influence on Regulation
The implications of such meetings raise significant questions about the integrity of regulatory processes. Whitney Di Bona, a consumer safety advocate, underscored the troubling nature of a major pesticide company’s CEO having private discussions with the EPA to mitigate liability concerns. She highlighted the disparity in access, noting that the voices of those harmed by glyphosate are often unheard in these crucial conversations.
Experts like Naomi Oreskes, a Harvard professor studying corporate influence in regulation, noted that this pattern of industry access to government officials is particularly alarming. It underscores an imbalance that favours corporate interests over the concerns of everyday citizens.
Zen Honeycutt, founder of Moms Across America, voiced her dismay at the revelations, pointing out that such coercive tactics by chemical companies are not new. Despite her organisation’s repeated attempts to engage with EPA leadership, she lamented the lack of meaningful action on calls to restrict or ban harmful pesticides.
Why it Matters
The implications of this meeting extend far beyond Bayer and glyphosate litigation; they shine a light on the broader issue of corporate influence in public health regulation. As regulatory agencies like the EPA navigate the complex interplay of industry interests and public safety, the potential for compromised decision-making looms large. The outcome of this legal battle could set a precedent for corporate accountability and the future of consumer safety in the face of powerful lobbying efforts. As the Supreme Court prepares to hear Bayer’s case, the stakes for public health and environmental safety have never been higher.
